{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T18:21:05Z","timestamp":1790446865634,"version":"4.1.0"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","license":[{"start":{"date-parts":[[2015,8,1]],"date-time":"2015-08-01T00:00:00Z","timestamp":1438387200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Urology"],"published-print":{"date-parts":[[2015,8]]},"DOI":"10.1016\/j.juro.2015.03.096","type":"journal-article","created":{"date-parts":[[2015,4,13]],"date-time":"2015-04-13T10:13:37Z","timestamp":1428920017000},"page":"297-303","source":"Crossref","is-referenced-by-count":82,"title":["A Phase II Study of Pazopanib in Patients with Localized Renal Cell Carcinoma to Optimize Preservation of Renal Parenchyma"],"prefix":"10.1097","volume":"194","author":[{"given":"Brian I.","family":"Rini","sequence":"first","affiliation":[{"name":"Department of Urology, Cleveland Clinic, Cleveland, Ohio"},{"name":"Department of Hematology and Oncology, Cleveland Clinic, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth R.","family":"Plimack","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshio","family":"Takagi","sequence":"additional","affiliation":[{"name":"Department of Urology, Cleveland Clinic, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Elson","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Cleveland Clinic, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura S.","family":"Wood","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Cleveland Clinic, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Dreicer","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Cleveland Clinic, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Gilligan","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Cleveland Clinic, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Garcia","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Cleveland Clinic, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiling","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Urology, Cleveland Clinic, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jihad","family":"Kaouk","sequence":"additional","affiliation":[{"name":"Department of Urology, Cleveland Clinic, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Venkatesh","family":"Krishnamurthi","sequence":"additional","affiliation":[{"name":"Department of Urology, Cleveland Clinic, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Stephenson","sequence":"additional","affiliation":[{"name":"Department of Urology, Cleveland Clinic, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amr","family":"Fergany","sequence":"additional","affiliation":[{"name":"Department of Urology, Cleveland Clinic, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric A.","family":"Klein","sequence":"additional","affiliation":[{"name":"Department of Urology, Cleveland Clinic, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert G.","family":"Uzzo","sequence":"additional","affiliation":[{"name":"Department of Urology, Fox Chase Cancer Center, Philadelphia, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David Y.T.","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Urology, Fox Chase Cancer Center, Philadelphia, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven C.","family":"Campbell","sequence":"additional","affiliation":[{"name":"Department of Urology, Cleveland Clinic, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"10.1016\/j.juro.2015.03.096_bib1","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/S0022-5347(05)66066-1","article-title":"Nephron sparing surgery for renal tumors: indications, techniques and outcomes","volume":"166","author":"Uzzo","year":"2001","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2015.03.096_bib2","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/j.juro.2014.04.016","article-title":"Chronic kidney disease due to surgical removal of nephrons: relative rates of progression and survival","volume":"192","author":"Demirjian","year":"2014","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2015.03.096_bib3","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1016\/j.juro.2009.07.004","article-title":"Guideline for management of the clinical T1 renal mass","volume":"182","author":"Campbell","year":"2009","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2015.03.096_bib4","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1158\/1078-0432.CCR-07-4089","article-title":"Sunitinib for treatment of advanced renal cell cancer: primary tumor response","volume":"14","author":"van der Veldt","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.juro.2015.03.096_bib5","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJMoa065044","article-title":"Sunitinib versus interferon alfa in metastatic renal-cell carcinoma","volume":"356","author":"Motzer","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.juro.2015.03.096_bib6","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s00345-010-0642-3","article-title":"Response of renal lesions during systemic treatment with sunitinib in patients with metastatic renal cell carcinoma: a single center experience with 14 patients","volume":"29","author":"Seidel","year":"2011","journal-title":"World J Urol"},{"key":"10.1016\/j.juro.2015.03.096_bib7","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1200\/JCO.2009.23.9764","article-title":"Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial","volume":"28","author":"Sternberg","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.juro.2015.03.096_bib8","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1200\/JCO.2008.21.6994","article-title":"Efficacy and safety of pazopanib in patients with metastatic renal cell carcinoma","volume":"28","author":"Hutson","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.juro.2015.03.096_bib9","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/S0140-6736(09)60229-4","article-title":"Renal cell carcinoma","volume":"373","author":"Rini","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.juro.2015.03.096_bib10","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1016\/j.juro.2011.12.075","article-title":"The effect of sunitinib on primary renal cell carcinoma and facilitation of subsequent surgery","volume":"187","author":"Rini","year":"2012","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2015.03.096_bib11","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1093\/annonc\/mdq564","article-title":"The safety and efficacy of sunitinib before planned nephrectomy in metastatic clear cell renal cancer","volume":"22","author":"Powles","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.juro.2015.03.096_bib12","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.eururo.2007.11.006","article-title":"Neoadjuvant sutent induction therapy may effectively down-stage renal cell carcinoma atrial thrombi","volume":"53","author":"Karakiewicz","year":"2008","journal-title":"Eur Urol"},{"key":"10.1016\/j.juro.2015.03.096_bib13","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1464-410X.2008.07660.x","article-title":"Neoadjuvant targeted therapy and advanced kidney cancer: observations and implications for\u00a0a new treatment paradigm","volume":"102","author":"Shuch","year":"2008","journal-title":"BJU Int"},{"key":"10.1016\/j.juro.2015.03.096_bib14","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/j.eururo.2014.01.035","article-title":"Phase 2 trial of neoadjuvant axitinib in patients with locally advanced nonmetastatic clear cell renal cell carcinoma","volume":"66","author":"Karam","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.juro.2015.03.096_bib15","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1016\/j.eururo.2011.02.032","article-title":"The\u00a0impact of targeted molecular therapies on the level of renal cell carcinoma vena caval tumor thrombus","volume":"59","author":"Cost","year":"2011","journal-title":"Eur Urol"},{"key":"10.1016\/j.juro.2015.03.096_bib16","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/j.juro.2009.05.014","article-title":"Surgical resection of renal cell carcinoma after targeted therapy","volume":"182","author":"Thomas","year":"2009","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2015.03.096_bib17","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1016\/j.eururo.2011.05.032","article-title":"Safety of presurgical targeted therapy in the setting of metastatic renal cell carcinoma","volume":"60","author":"Chapin","year":"2011","journal-title":"Eur Urol"},{"key":"10.1016\/j.juro.2015.03.096_bib18","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1097\/01.sla.0000133083.54934.ae","article-title":"Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey","volume":"240","author":"Dindo","year":"2004","journal-title":"Ann Surg"},{"key":"10.1016\/j.juro.2015.03.096_bib19","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.juro.2013.12.035","article-title":"Predictors of precision of excision and reconstruction in partial nephrectomy","volume":"192","author":"Takagi","year":"2014","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2015.03.096_bib20","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New\u00a0guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.juro.2015.03.096_bib21","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1038\/nrurol.2013.34","article-title":"Oncological and renal medical importance of kidney-sparing surgery","volume":"10","author":"Russo","year":"2013","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.juro.2015.03.096_bib22","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1016\/j.juro.2015.01.093","article-title":"Decline in renal function after partial nephrectomy: etiology and prevention","volume":"193","author":"Mir","year":"2015","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2015.03.096_bib23","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.urology.2013.03.068","article-title":"Parenchymal volume preservation and ischemia during partial nephrectomy: functional and volumetric analysis","volume":"82","author":"Mir","year":"2013","journal-title":"Urology"},{"key":"10.1016\/j.juro.2015.03.096_bib24","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.juro.2012.02.2574","article-title":"Nephrometry score is associated with volume loss and functional recovery after partial nephrectomy","volume":"188","author":"Simmons","year":"2012","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2015.03.096_bib25","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1053\/j.seminoncol.2013.05.004","article-title":"Adjuvant therapy in renal cell carcinoma\u2014past, present, and future","volume":"40","author":"Janowitz","year":"2013","journal-title":"Semin Oncol"}],"container-title":["Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022534715033984?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022534715033984?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.jurology.com\/doi\/pdf\/10.1016\/j.juro.2015.03.096","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,29]],"date-time":"2022-04-29T00:04:40Z","timestamp":1651190680000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jurology.com\/doi\/10.1016\/j.juro.2015.03.096"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,8]]}},"alternative-id":["10.1016\/j.juro.2015.03.096"],"URL":"https:\/\/doi.org\/10.1016\/j.juro.2015.03.096","relation":{},"ISSN":["0022-5347","1527-3792"],"issn-type":[{"value":"0022-5347","type":"print"},{"value":"1527-3792","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,8]]}}}